Intermittent Catheterization Versus Trial Without Catheter
NCT ID: NCT05094947
Last Updated: 2021-10-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
200 participants
INTERVENTIONAL
2021-08-03
2022-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
intermittent catheterization (group B)
Procedure/Surgery: The acute urinary retention in group B is managed by clean intermittent catheterization along with alpha-blockers during 3 period. After 3 days the ability of spontaneous voiding is assessed and registered as an outcome.
intermittent catheterization
clean intermittent catheterization with catheter Nelaton
alpha-blockers
tamsulosin, alfuzosin, doxazosin, silodosin
Catheter Foley (group A)
The acute urinary retention in group A is managed by trial without catheter along with alpha-blockers during 3 period. After 3 days the indwelling Foley catheter is removed and ability of spontaneous voiding is assessed and registered as an outcome.
trial without catheter
catheter Foley
alpha-blockers
tamsulosin, alfuzosin, doxazosin, silodosin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
intermittent catheterization
clean intermittent catheterization with catheter Nelaton
trial without catheter
catheter Foley
alpha-blockers
tamsulosin, alfuzosin, doxazosin, silodosin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Previous urethral or prostate surgery.
* Urethral stricture.
* Urethrorrhagia.
* Injuries of urethra and perineum.
* Attempts of bladder catheterization within 15 days before the acute urinary retention episode.
* Urinary tract infection.
* Neurogenic bladder.
* Chronic urinary retention with a bladder volume of more than 1 liter.
* Obstructive uropathy due to the acute urinary retention.
21 Years
95 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Moscow State University of Medicine and Dentistry
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vigen Malkhasyan
Role: PRINCIPAL_INVESTIGATOR
Moscow state university of medicine and dentistry named after A.I. Evdokimov
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Moscow state university of medicine and dentistry named after A.I. Evdokimov
Moscow, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Vigen Malkhasyan
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Moscow MSUMD
Identifier Type: -
Identifier Source: org_study_id